• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Gynecologic Oncology

Gynecologic Oncology

  • Contact Us
  • 888-GYNONC1

Clinical Trials

GYN 106

Advanced Ovarian Cancer: Platinum Sensitive

Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Cancer Types: Ovarian

Lines of Therapy: 3rd Line+ Metastatic

View Details on ClinicalTrials.gov

Back to Clinical Trials

GYN 103

Advanced Ovarian Cancer: Platinum resistant

(EPIK-O) A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer

Cancer Types: GYN, Ovarian

Lines of Therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

View Details on ClinicalTrials.gov

Back to Clinical Trials

GYN 104 AVB500-OC-004

Advanced Ovarian Cancer: Platinum resistant

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Cancer Types: GYN, Ovarian

Lines of Therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

View Details on ClinicalTrials.gov

Back to Clinical Trials

GYN 101 EP0057-201

Advanced Ovarian Cancer: Platinum resistant, Advanced Ovarian Cancer: Platinum sensitive

A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with olaparib in advanced ovarian cancer patients.

Cancer Types: GYN, Ovarian

Lines of Therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

View Details on ClinicalTrials.gov

Back to Clinical Trials

Footer

 

To schedule an appointment:

888-GYNONC1

 

Copyright © 2025 Gynecologic Oncology